# Sven Mahner

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sven-mahner/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,243 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 38 |
| i10-index | 108 |
| Last Known Institution | Universität Hamburg |
| OpenAlex ID | https://openalex.org/A5056412323 |
| ORCID iD | 0000-0002-0640-129X |
| Works | 327 |

## Researcher papers

- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial](https://scholariq.org/papers/olaparib-combined-with-chemotherapy-for-recurrent-platinum-sensitive-ovarian/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023](https://scholariq.org/papers/european-society-of-gynaecological-oncology-guidelines-for-the-management-of-2/)
- [European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer](https://scholariq.org/papers/european-society-of-gynaecological-oncology-guidelines-for-the-management-of/)
- [Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial](https://scholariq.org/papers/niraparib-maintenance-therapy-in-patients-with-recurrent-ovarian-cancer-after-a/)
- [Safety and dose modification for patients receiving niraparib](https://scholariq.org/papers/safety-and-dose-modification-for-patients-receiving-niraparib/)
- [TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)](https://scholariq.org/papers/trust-trial-of-radical-upfront-surgical-therapy-in-advanced-ovarian-cancer-engot/)
- [Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine](https://scholariq.org/papers/expression-and-localization-of-the-multidrug-resistance-associated-protein-3-in/)
- [European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer](https://scholariq.org/papers/european-experts-consensus-brca-homologous-recombination-deficiency-testing-in/)
- [MR pelvimetry: prognosis for successful vaginal delivery in patients with suspected fetopelvic disproportion or breech presentation at term](https://scholariq.org/papers/mr-pelvimetry-prognosis-for-successful-vaginal-delivery-in-patients-with/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Reproductive System and Pregnancy](https://scholariq.org/topics/reproductive-system-and-pregnancy/)

## Researcher university

- [Universität Hamburg](https://scholariq.org/institutions/universitat-hamburg/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.